NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.01. View Eiger Biopharmaceuticals' Earnings History.

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eiger Biopharmaceuticals.

6 analysts have issued 12 month target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $47.00. On average, they anticipate Eiger Biopharmaceuticals' share price to reach $29.14 in the next twelve months. This suggests a possible upside of 119.1% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

Media stories about EIGR stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 475,400 shares, a decline of 8.9% from the December 31st total of 521,800 shares. Based on an average daily trading volume, of 175,700 shares, the days-to-cover ratio is currently 2.7 days. Currently, 2.2% of the shares of the company are short sold. View Eiger Biopharmaceuticals' Current Options Chain.

Some companies that are related to Eiger Biopharmaceuticals include Orchard Therapeutics (ORTX), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM), Oyster Point Pharma (OYST), Vericel (VCEL), Proteon Therapeutics (PRTO) and GENFIT S A/ADR (GNFT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Concert Pharmaceuticals (CNCE), Exelixis (EXEL), Amarin (AMRN), Celldex Therapeutics (CLDX) and Catalyst Pharmaceuticals (CPRX).

Eiger Biopharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Tocqueville Asset Management L.P. (0.21%) and Sanders Morris Harris LLC (0.19%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Joanne Quan, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC and Tocqueville Asset Management L.P.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $13.30.

Eiger Biopharmaceuticals has a market capitalization of $325.85 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]